-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Currently, there is an urgent need for accurate biomarkers to diagnose early neurodegenerative diseases, such as Alzheimer's disease (AD) and Lewy body disease (LB).
diagnosis
Recently, reports of unsuccessful new treatments for Alzheimer's disease may be related to these treatments being performed late in the course of the disease.
consensus
Sympathetic neuroimaging of mIBG can distinguish possible MCI-LB and MCI-AD cases.
They included 95 patients with mild cognitive impairment.
For a symptom-only diagnosis, the accuracy of mIBG is 79% (95% CI: 68 to 87%), and the accuracy of FP-CIT is 76% (95% CI: 65 to 85%).
The accuracy of mIBG was 79% (95% CI: 68 to 87%), and the accuracy of FP-CIT was 76% (95% CI: 65 to 85%).
It is found that cardiac mIBG is very useful in early diseases, and abnormal scans are highly indicative of MCI-LB.
ncbi.
nlm.
nih.
gov/33883238/" target="_blank" rel="noopener">Accuracy of Cardiac Innervation Scintigraphy for Mild Cognitive Impairment With Lewy Bodies
ncbi.
nlm.
nih.
gov/33883238/" target="_blank" rel="noopener">Gemma Roberts, Rory Durcan MRCPI, Paul C Donaghy, Sarah Lawley, Joanna Ciafone, Calum A Hamilton, Sean J Colloby, Michael J Firbank, Louise Allan, Nicola Barnett, Sally Barker, Kim Howe, Tamir Ali, George S Petrides, Jim Lloyd, John-Paul Taylor, John O'Brien, Alan J Thomas
leave a message here